Global Adderall Drug Market Report and Forecast 2024-2032

Global Adderall Drug Market Outlook

The global Adderall drug market size is being driven by the rising prevalence of ADHD, which was close to USD 20.90 billion in 2023. The market is expected to grow with a CAGR of 4% during the forecast period of 2024-2032. The market is expected to reach a value of about USD 29.75 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Adderall Insights

Adderall is a trade name of the drug amphetamine. It is an FDA-approved prescription drug and first choice treatment option for attention deficit hyperactivity disorder (ADHD). It is also used for the treatment of narcolepsy, a chronic sleep disorder that is characterised by extreme daytime sleepiness and unexpected sleep episodes. 

ADHD at a Glance

ADHD is a heterogeneous neurodevelopmental syndrome that comprises hyperactivity, increased impulsivity, and developmentally inappropriate inattentiveness. Multiple aspects of life are greatly hampered by ADHD, which can result in underachievement in school, unemployment, a failed marriage, and criminal activity, among other things. 

Additionally, several comorbid mental problems, such as antisocial personality disorder, self-harm, and substance abuse, exhibit substantial correlations with ADHD, inflict significant burden on families and society.

Dosage and Side Effects of Adderall

Usage of Adderall for a prolonged period may lead to dependency or misuse of the drug and resultant adverse cardiovascular events. The effectiveness of Adderall in long-term use has not been evaluated in clinical trials thoroughly, therefore, when prescribed, it is necessary to re-evaluate the efficacy of the drug periodically by physicians.

Contraindications of Adderall are arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, hypersensitivity (idiosyncrasy to sympathomimetics amines, and glaucoma. 

Some serious side effects include slow growth in children, seizures, blurred vision, or change in eyesight whereas some common side effects of this drug consist of headache, stomachache, trouble sleeping, decreased appetite, nervousness, and dizziness, among others.

Adderall Drug Market Scenario

The market is further divided into the following segmentations:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Disease Treatment

• Attention Deficit Hyperactivity Disorder (ADHD)
  • Necrolepsy
  • Others

Market Breakup by Distribution Channel

• Hospital-based pharmacies
• Retail pharmacies
• Others

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Telehealth Prescription Propelling the Adderall Drug Market

The rising demand of Adderall drug market can be attributed to telehealth prescriptions of controlled substances like Adderall and Ritalin by online mental health care startups that were established during the pandemic and were permitted to do so by the US Drug Enforcement Agency.

Global Scenario for Adderall

Globally, ADHD is estimated to be affecting about 5% of children and teenagers. Due to the lack of standardised diagnostic criteria, adult ADHD appears to be overlooked in epidemiology. One of the most commonly given stimulants, along with Adderall are Ritalin and Concerta.

Cognitive and memory enhancer medications, supplements, and other substances are claimed to boost cognitive function in healthy persons, notably executive functions, attention, memory, creativity, or motivation. These medications comprise a variety of compounds that can boost cognitive performance and can increase or retain memory, stimulate learning, or prevent cognitive decline or dementia.

ADHD diagnosis can differ on the basis of age group and gender. Based on age group, the average age of ADHD diagnosis in children in the United States is about seven years, there is an increase of about two times in the cases of ADHD over the past ten years. The first signs and symptoms of ADHD are typically expected to appear between the age group of 3-6 years.

About 4% of adult Americans are dealing with ADHD symptoms on daily basis. Based on gender, the male population is about 3 times more likely to be diagnosed with ADHD than the female population.

Adderall Market Trends

The market is also rising with the rapid increase in the senior population, which is more vulnerable to neurological illnesses, such as Alzheimer's. Increased usage of cognitive medicines due to benefits, such as improved physical and mental performance, drives the market growth further. However, ethical concerns about the use of such pharmaceuticals can limit the market growth.

Therapeutic Landscape of Adderall

ADHD is treated with short, intermediate, and long-acting forms of stimulants. Adderall, being a short-acting stimulant, is usually consumed 2-3 times a day and has better control when it is in the system but it is difficult to keep the dose intake persistent on daily basis.

Amphetamine is a medication that is used to manage and treat ADHD and narcolepsy. It is classified as a stimulant of the central nervous system. Amphetamine has been shown to increase the concentrations of noradrenaline in the prefrontal cortex and dopamine in the striatum in a dose and time-dependent manner. The indistinct release of neurotransmitters such as adrenaline is known to have cardiovascular side effects.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Intas Pharmaceuticals

• Aztiq Pharma Partners

• Ascent Pharms, Inc.

• Aurolife Pharma LLC

• Cediprof, Inc.

• Elite Labs, Inc.

• PuraCap Pharmaceutical

• Granules Pharmaceutical, Inc.

• Nuvo Pharm

• Shire LLC (Takeda Pharmaceutical Company Limited)

• Rhodes Pharma

• Zydus Lifesciences Limited 

• Teva Pharmaceutical

Key Highlights of the Report